Volume 14, Issue 9, Pages (September 2017)

Slides:

Advertisements

Similar presentations

EWOLUTION: 3-months outcome of Left Atrial Appendage Closure with the WATCHMAN device in Europe Thrombus at the device, leakage at follow-up, device embolisation,

Advertisements

LAAC: What Does the Post Marketing Data Tell Us?

CHA2DS2-VASC and CHADS2 Scores Predict Adverse Clinical Events in Patients With Pacemakers and Sinus Node Dysfunction Independent of Atrial Fibrillation

Update on the Watchman Device CRT 2010 Washington, DC

2016 Guidelines of the Taiwan Heart Rhythm Society and the Taiwan Society of Cardiology for the management of atrial fibrillation Chern-En Chiang, Tsu-Juey.

David R. Holmes, Jr., M.D. Mayo Clinic, Rochester

Figure 1 Flow chart diagram of high-risk group AF patients

Volume 28, Issue 6, Pages (December 2012)

Differences and trends in stroke prevention anticoagulation in primary care vs cardiology specialty management of new atrial fibrillation: The Retrospective.

CHA2DS2-VASc Scoring System General AF Treatment Guidance.

Volume 14, Issue 6, Pages (June 2017)

Role of the CHADS2 Score in Acute Coronary Syndromes

Renato D. Lopes, MD, PhD, Li Li, MS, Christopher B

Focused 2012 Update of the Canadian Cardiovascular Society Atrial Fibrillation Guidelines: Recommendations for Stroke Prevention and Rate/Rhythm Control

Volume 15, Issue 1, Pages (January 2018)

Volume 13, Issue 11, Pages (November 2016)

Niv Ad, MD, Linda Henry, PhD, RN, Deborah J. Shuman, BS, Sari D

CHA2DS2-VASc Score Is Directly Associated with the Risk of Pulmonary Embolism in Patients with Atrial Fibrillation Walid Saliba, MD, MPH, Gad Rennert,

Volume 12, Issue 1, Pages (January 2015)

Volume 14, Issue 9, Pages (September 2017)

Left atrial appendage closure: A new technique for clinical practice

Watching for the Patient With AF: Latest Advances and Technologies

Net Clinical Benefit of Non-vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Phase III Atrial Fibrillation Trials Giulia Renda, MD, PhD, Marta.

Efficacy and Safety of Non-Vitamin K Antagonist Oral Anticoagulants After Cardioversion for Nonvalvular Atrial Fibrillation Giulia Renda, MD, PhD, Marco.

Relative Risk of Events by CHA2DS2-VASc Score

Alexander M. Walker, MD, DrPH, Dimitri Bennett, MD, MPH Heart Rhythm

Volume 13, Issue 1, Pages (January 2016)

Volume 14, Issue 6, Pages (June 2017)

Alexander M. Walker, MD, DrPH, Dimitri Bennett, MD, MPH Heart Rhythm

Gregory Y.H. Lip, MD, Jonathan L. Halperin, MD, Hung-Fat Tse, MD, PhD

Volume 12, Issue 6, Pages (June 2015)

Volume 13, Issue 1, Pages (January 2016)

Volume 8, Issue 12, Pages (December 2011)

Volume 13, Issue 3, Pages (March 2016)

Triple vs Dual Antithrombotic Therapy in Patients with Atrial Fibrillation and Coronary Artery Disease Renato D. Lopes, MD, MHS, PhD, Meena Rao, MD,

Volume 15, Issue 3, Pages (March 2018)

Volume 7, Issue 1, Pages (January 2010)

CHADS2 Score, Statin Therapy, and Risks of Atrial Fibrillation

Hong-Tao Tie, MD, Rui Shi, MD The American Journal of Medicine

Volume 12, Issue 7, Pages (July 2015)

Left atrial appendage exclusion: An alternative to anticoagulation in nonvalvular atrial fibrillation Kareem Bedeir, MBChB, MS, David R. Holmes, MD,

Isla M. Ogilvie, PhD, Nick Newton, PhD, Sharon A

Improving Outcomes in AF: Do the NOACs Hold Their Promise In The Real World?

Volume 15, Issue 12, Pages (December 2018)

HeartRhythm Case Reports

Volume 8, Issue 12, Pages (December 2011)

Case-Based Discussion Regarding Challenges in Patient Selection and Procedural Planning in Left Atrial Appendage Occlusion Sidakpal S. Panaich, MD, Thomas.

Volume 16, Issue 1, Pages e3-e16 (January 2019)

The risk and extent of neurologic events are equivalent for high-risk patients treated with transcatheter or surgical aortic valve replacement Thomas.

Volume 5, Issue 7, Pages (July 2008)

Volume 9, Issue 1, Pages (January 2012)

Volume 14, Issue 3, Pages (March 2017)

Volume 14, Issue 12, Pages (December 2017)

5 Good Minutes on Atrial Fibrillation-related Stroke

Volume 16, Issue 1, Pages 3-9 (January 2019)

Volume 9, Issue 8, Pages S14-S17 (August 2012)

Michael R. Gold, MD, PhD, FHRS Heart Rhythm

Termination of anticoagulation therapy at 45 days after concomitant atrial fibrillation catheter ablation and left atrial appendage occlusion resulting.

Canadian Cardiovascular Society Atrial Fibrillation Guidelines 2010: Prevention of Stroke and Systemic Thromboembolism in Atrial Fibrillation and Flutter

Stroke and Bleeding Risk Co-distribution in Real-world Patients with Atrial Fibrillation: The Euro Heart Survey Maura Marcucci, MD, Gregory Y.H. Lip,

Volume 8, Issue 1, Pages (January 2011)

Epicardial appendage ooze causing pericardial tamponade after left atrial appendage device implantation Karen P. Phillips, MBBS, FHRS, Christopher Smith,

Volume 10, Issue 9, Pages (September 2013)

The American Journal of Medicine

Left Atrial Appendage Occlusion for The Unmet Clinical Needs of Stroke Prevention in Nonvalvular Atrial Fibrillation David R. Holmes, MD, Mohamad Alkhouli,

Cardiovascular and cerebrovascular events among patients receiving omalizumab: Pooled analysis of patient-level data from 25 randomized, double-blind,

Efficacy and Safety of Non-Vitamin K Antagonist Oral Anticoagulants After Cardioversion for Nonvalvular Atrial Fibrillation Giulia Renda, MD, PhD, Marco.

Figure 8. Stroke prevention strategy in patients with AF

The CHA(2)DS2-(VASc) stroke risk and HAS-BLED bleeding risk index are calculated by totalling the scores for each risk factor present.68–71 The lower graph.

Volume 14, Issue 6, Pages (June 2017)

Presentation transcript:

Volume 14, Issue 9, Pages 1302-1308 (September 2017) Efficacy and safety of left atrial appendage closure with WATCHMAN in patients with or without contraindication to oral anticoagulation: 1-Year follow-up outcome data of the EWOLUTION trial Lucas V. Boersma, MD, PhD, FESC, Hueseyin Ince, MD, Stephan Kische, MD, Evgeny Pokushalov, MD, PhD, Thomas Schmitz, MD, Boris Schmidt, MD, Tommaso Gori, MD, Felix Meincke, MD, Alexey Vladimir Protopopov, MD, PhD, Timothy Betts, MD, David Foley, MD, PhD, FRCPI, FACA, FACC, FESC, Horst Sievert, MD, Patrizio Mazzone, MD, Tom De Potter, MD, Elisa Vireca, MS, Kenneth Stein, MD, FHRS, Martin W. Bergmann, MD, PhD, FESC Heart Rhythm Volume 14, Issue 9, Pages 1302-1308 (September 2017) DOI: 10.1016/j.hrthm.2017.05.038 Copyright © 2017 The Authors Terms and Conditions

Figure 1 Flow chart of all patients included in EWOLUTION throughout 1-year follow-up. FU = follow-up; Pts = patients; TEE = transesophageal echocardiography. Heart Rhythm 2017 14, 1302-1308DOI: (10.1016/j.hrthm.2017.05.038) Copyright © 2017 The Authors Terms and Conditions

Figure 2 Flowchart of anti-coagulation drugs used after WATCHMAN implant throughout 1-year follow-up. DAPT = dual antiplatelet therapy; FU = follow-up; OAC = oral anticoagulation; Pts = patients; sAPT = single antiplatelet therapy. Heart Rhythm 2017 14, 1302-1308DOI: (10.1016/j.hrthm.2017.05.038) Copyright © 2017 The Authors Terms and Conditions

Figure 3 Actual stroke rate, and calculated stroke risk based on CHA2DS2-VASc score, and the relative risk reduction for the total EWOLUTION patient cohort after 1-year follow-up. RR = relative risk; SE = systemic embolism; TIA = transient ischemic attack. Heart Rhythm 2017 14, 1302-1308DOI: (10.1016/j.hrthm.2017.05.038) Copyright © 2017 The Authors Terms and Conditions

Figure 4 Actual major bleeding rate excluding procedural bleeding events, and calculated major bleeding risk based on HAS-BLED score, and the relative risk reduction for the total EWOLUTION patient cohort after 1-year follow-up. RR = relative risk; SE = systemic embolism; TIA = transient ischemic attack. Heart Rhythm 2017 14, 1302-1308DOI: (10.1016/j.hrthm.2017.05.038) Copyright © 2017 The Authors Terms and Conditions